Cargando…
How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes
This pedagogical review illustrates the differences between pharmacokinetic (PK) and pharmacodynamic (PD) measures, using insulin therapy as the primary example. The main conclusion is that PD parameters are of greater clinical significance for insulin therapy than PK parameters. The glucose-clamp t...
Autores principales: | Arnolds, S, Kuglin, B, Kapitza, C, Heise, T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2984539/ https://www.ncbi.nlm.nih.gov/pubmed/20618882 http://dx.doi.org/10.1111/j.1742-1241.2010.02470.x |
Ejemplares similares
-
Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes
por: Heise, Tim, et al.
Publicado: (2016) -
Pharmacokinetics, pharmacodynamics, and safety of prandial oral insulin (N11005) in healthy subjects
por: Pan, Qi, et al.
Publicado: (2023) -
Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
por: Heise, Tim, et al.
Publicado: (2009) -
Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus
por: Grant, Marshall, et al.
Publicado: (2021) -
A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
por: Haahr, Hanne, et al.
Publicado: (2016)